AbbVie Inc. is 81.7x more valuable than Amneal Pharmaceuticals, Inc. by market capitalization ($399.47 B vs $4.89 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AMRX | ABBV |
|---|---|---|
| Market cap | $4.89 B | $399.47 B |
| US-listed rank | #1397 | #28 |
| Revenue (latest FY) | $3.02B | $61.16B |
| Net income (latest FY) | $72.06M | $4.23B |
| Net margin | 2.4% | 6.9% |
| P/E (trailing FY) | 67.8 | 94.5 |
| SEC filings | 664 | 1,008 |
AbbVie Inc. is 81.7x more valuable than Amneal Pharmaceuticals, Inc. by market capitalization ($399.47 B vs $4.89 B).
In their latest fiscal years, Amneal Pharmaceuticals, Inc. reported $3.02B in revenue while AbbVie Inc. reported $61.16B.
Full pages: Amneal Pharmaceuticals, Inc. and AbbVie Inc., or browse the full rankings.